vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and KILROY REALTY CORP (KRC). Click either name above to swap in a different company.
KILROY REALTY CORP is the larger business by last-quarter revenue ($272.2M vs $139.2M, roughly 2.0× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 6.3%, a 29.2% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -5.0%). KILROY REALTY CORP produced more free cash flow last quarter ($450.3M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -1.2%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Kilroy Realty Corp is a leading U.S. real estate investment trust that develops, owns, and operates premium office, life science, and mixed-use properties primarily across high-growth West Coast markets including Los Angeles, San Francisco, Seattle, and San Diego. It serves tenants across the technology, life sciences, media, and creative sectors, with a core focus on delivering sustainable, future-ready workspaces tailored to modern business needs.
ADMA vs KRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $272.2M |
| Net Profit | $49.4M | $17.1M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | — |
| Net Margin | 35.5% | 6.3% |
| Revenue YoY | 18.4% | -5.0% |
| Net Profit YoY | -55.9% | -73.7% |
| EPS (diluted) | $0.20 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $272.2M | ||
| Q3 25 | $134.2M | $279.7M | ||
| Q2 25 | $122.0M | $289.9M | ||
| Q1 25 | $114.8M | $270.8M | ||
| Q4 24 | $117.5M | $286.4M | ||
| Q3 24 | $119.8M | $289.9M | ||
| Q2 24 | $107.2M | $280.7M | ||
| Q1 24 | $81.9M | $278.6M |
| Q4 25 | $49.4M | $17.1M | ||
| Q3 25 | $36.4M | $162.3M | ||
| Q2 25 | $34.2M | $79.6M | ||
| Q1 25 | $26.9M | $43.7M | ||
| Q4 24 | $111.9M | $65.0M | ||
| Q3 24 | $35.9M | $57.7M | ||
| Q2 24 | $32.1M | $54.5M | ||
| Q1 24 | $17.8M | $55.7M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | — | ||
| Q3 25 | 38.0% | — | ||
| Q2 25 | 35.1% | — | ||
| Q1 25 | 30.4% | — | ||
| Q4 24 | 32.6% | — | ||
| Q3 24 | 33.1% | — | ||
| Q2 24 | 36.6% | — | ||
| Q1 24 | 26.7% | — |
| Q4 25 | 35.5% | 6.3% | ||
| Q3 25 | 27.1% | 58.0% | ||
| Q2 25 | 28.1% | 27.4% | ||
| Q1 25 | 23.4% | 16.1% | ||
| Q4 24 | 95.2% | 22.7% | ||
| Q3 24 | 30.0% | 19.9% | ||
| Q2 24 | 29.9% | 19.4% | ||
| Q1 24 | 21.7% | 20.0% |
| Q4 25 | $0.20 | $0.11 | ||
| Q3 25 | $0.15 | $1.31 | ||
| Q2 25 | $0.14 | $0.57 | ||
| Q1 25 | $0.11 | $0.33 | ||
| Q4 24 | $0.45 | $0.50 | ||
| Q3 24 | $0.15 | $0.44 | ||
| Q2 24 | $0.13 | $0.41 | ||
| Q1 24 | $0.08 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $179.3M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $5.4B |
| Total Assets | $624.2M | $10.9B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $179.3M | ||
| Q3 25 | $61.4M | $372.4M | ||
| Q2 25 | $90.3M | $193.1M | ||
| Q1 25 | $71.6M | $146.7M | ||
| Q4 24 | $103.1M | $165.7M | ||
| Q3 24 | $86.7M | $625.4M | ||
| Q2 24 | $88.2M | $835.9M | ||
| Q1 24 | $45.3M | $855.0M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $5.4B | ||
| Q3 25 | $431.2M | $5.5B | ||
| Q2 25 | $398.3M | $5.4B | ||
| Q1 25 | $373.4M | $5.4B | ||
| Q4 24 | $349.0M | $5.4B | ||
| Q3 24 | $231.9M | $5.4B | ||
| Q2 24 | $188.3M | $5.4B | ||
| Q1 24 | $153.7M | $5.4B |
| Q4 25 | $624.2M | $10.9B | ||
| Q3 25 | $568.7M | $11.0B | ||
| Q2 25 | $558.4M | $10.9B | ||
| Q1 25 | $510.6M | $10.9B | ||
| Q4 24 | $488.7M | $10.9B | ||
| Q3 24 | $390.6M | $11.4B | ||
| Q2 24 | $376.4M | $11.5B | ||
| Q1 24 | $350.9M | $11.6B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $566.3M |
| Free Cash FlowOCF − Capex | $34.6M | $450.3M |
| FCF MarginFCF / Revenue | 24.8% | 165.4% |
| Capex IntensityCapex / Revenue | 0.8% | 42.6% |
| Cash ConversionOCF / Net Profit | 0.72× | 33.10× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $833.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $566.3M | ||
| Q3 25 | $13.3M | $176.6M | ||
| Q2 25 | $21.1M | $143.7M | ||
| Q1 25 | $-19.7M | $136.9M | ||
| Q4 24 | $50.2M | $541.1M | ||
| Q3 24 | $25.0M | $176.3M | ||
| Q2 24 | $45.6M | $88.7M | ||
| Q1 24 | $-2.2M | $167.9M |
| Q4 25 | $34.6M | $450.3M | ||
| Q3 25 | $-1.1M | $148.7M | ||
| Q2 25 | $18.7M | $118.4M | ||
| Q1 25 | $-24.4M | $115.6M | ||
| Q4 24 | $47.5M | $440.8M | ||
| Q3 24 | $24.0M | $147.2M | ||
| Q2 24 | $43.6M | $69.5M | ||
| Q1 24 | $-4.6M | $151.9M |
| Q4 25 | 24.8% | 165.4% | ||
| Q3 25 | -0.8% | 53.1% | ||
| Q2 25 | 15.3% | 40.9% | ||
| Q1 25 | -21.2% | 42.7% | ||
| Q4 24 | 40.4% | 153.9% | ||
| Q3 24 | 20.0% | 50.8% | ||
| Q2 24 | 40.7% | 24.7% | ||
| Q1 24 | -5.6% | 54.5% |
| Q4 25 | 0.8% | 42.6% | ||
| Q3 25 | 10.7% | 10.0% | ||
| Q2 25 | 2.0% | 8.7% | ||
| Q1 25 | 4.1% | 7.9% | ||
| Q4 24 | 2.3% | 35.0% | ||
| Q3 24 | 0.9% | 10.1% | ||
| Q2 24 | 1.9% | 6.8% | ||
| Q1 24 | 2.9% | 5.7% |
| Q4 25 | 0.72× | 33.10× | ||
| Q3 25 | 0.36× | 1.09× | ||
| Q2 25 | 0.62× | 1.81× | ||
| Q1 25 | -0.73× | 3.13× | ||
| Q4 24 | 0.45× | 8.32× | ||
| Q3 24 | 0.70× | 3.06× | ||
| Q2 24 | 1.42× | 1.63× | ||
| Q1 24 | -0.12× | 3.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
KRC
Segment breakdown not available.
